Drug intelligence / Profile preview

SpikoGen

Development stage
Phase 3
Lead developer
Cinnagen
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Oral, Sublingual
01

Overview

**SpikoGen** is an adjuvanted recombinant protein-subunit vaccine for prevention of COVID-19. It contains a recombinant prefusion-stabilized extracellular-domain trimer of the SARS-CoV-2 spike glycoprotein, produced in insect cells, formulated with the Advax-CpG55.2 adjuvant system. Vaccination induces spike-directed neutralizing antibodies and cellular immune responses intended to prevent SARS-CoV-2 infection and severe COVID-19. The product was developed by Vaxine in collaboration with CinnaGen, underwent pivotal Phase 3 evaluation, and has received Iranian authorization for COVID-19 prevention, including use in children aged 5 years and older. ([tandfonline.com](https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2363016))

Brand names
SpikoGenCovax-19Covax19Covax 19
Other names
COVAX-19COVAX19COVAX 19
02

Targets

TLR9 (Toll-like receptor 9)SARS-CoV-2 spike

Beyond the preview

Go deeper on SpikoGen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpikoGen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call